AstraZeneca and Bristol Myers Squibb in $400 billion merger talks

British pharmaceutical giant AstraZeneca is in talks to merge with US rival Bristol Myers Squibb, according to the Financial Times. The potential deal would be valued at around $400 billion, making it one of the largest transactions in pharmaceutical industry history.